Article Text

Download PDFPDF
Review: omalizumab reduces asthma exacerbations and daily steroid use

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with asthma, how effective is omalizumab, a recombinant humanised monoclonal antibody, in reducing asthma exacerbations and steroid use?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★☆☆☆ Respirology ★★★★★★☆


Embedded ImageData sources:

searching Cochrane Airways Group trials register, scanning the reference lists of relevant studies and review articles, reviewing abstracts presented at leading respiratory society meetings, contacting pharmaceutical companies manufacturing anti-immunoglobulin E (IgE) formulations, and contacting experts in the field.

Embedded ImageStudy selection and assessment:

randomised controlled trials comparing anti-IgE at any dose or route with placebo or conventional treatments in children and adults with chronic asthma.

Embedded ImageOutcomes:

reduction or termination of steroid use and asthma exacerbations (hospital admissions, emergency department visits, days lost from work or school, unscheduled physician visits, and increase in medication).


8 blinded, placebo controlled trials of …

View Full Text


  • Abstract and commentary also appear in ACP Journal Club.

  • For correspondence: Dr S Walker, National Respiratory Training Centre, Warwick, UK.

  • Source of funding: Garfield Weston Foundation UK.